From VUS Uncertainty
to Complete Care Plans
One system that handles everything: variant interpretation, drug ranking, resistance prediction, toxicity prevention, and trial matching. Complete care plans in minutes, not months.
Resolve Genetic Uncertainty
73% VUS resolution with zero-shot prediction
Match Patients to Therapies
100% Top-5 drug accuracy validated
Predict Resistance Early
6 months before imaging confirmation
Experience Complete Care Plan Intelligence
Click on any MOAT capability below to see how CrisPRO.ai transforms clinical decision-making with real-time demonstrations and validated results.
Match Patients to Therapies
S/P/E Framework (100% Top-5 accuracy)
Predict Resistance Before It Happens
MAPK/NF1 = 2x resistance risk (validated)
Prevent Toxicity Before It Happens
Toxicity-aware nutrition (THE PATIENT MOAT)
Match Patients to Clinical Trials
Mechanism-based trial matching
Identify Synthetic Lethality Vulnerabilities
Identify double-hit vulnerabilities
Patient Journey Transformation
From months of uncertainty to actionable insights in days
Traditional Approach
Genetic Testing & Variant Discovery
2 weeksComprehensive genomic sequencing reveals multiple variants of unknown significance
Literature Review & Expert Consultation
6 weeksManual research across databases and specialist consultations to interpret variants
Family Studies & Functional Assays
12 weeksCoordinate family member testing and expensive functional validation studies
Treatment Selection & Monitoring
8 weeksSelect therapy based on available evidence and monitor for resistance
Oracle-Powered Approach
Genetic Testing & Instant Oracle Analysis
2 daysGenomic sequencing with immediate zero-shot variant interpretation
SAE-Powered Explainable Evidence
1 dayMechanistic interpretability reveals biological features driving predictions
Resistance Pathway Prediction
3 daysPredict likely tumor evolution paths and design preemptive combination therapies
Personalized Immunotherapy Design
1 weekGenerate patient-specific neoantigens and CAR-T designs with structural validation
Key Workflow Improvements
Clinical Case Study: RUNX1 Leukemia
Predicting tumor evolution and designing preemptive combination therapies
Cell
Normal RUNX1
Hit
Inherited RUNX1
Mutation
Hit
Acquired Somatic
Mutation
Cell
Full-Blown
Leukemia
Known Genetic Risk
RUNX1 (First Hit)
Oracle Analysis
Predicted Mutations
Input:
Input: Disease Map
Forge Engine
Therapeutic Arsenal
Clinical Impact
Traditional Approach
- • React to resistance after it develops
- • Sequential monotherapy trials
- • 6-month average response duration
- • Limited treatment options
Oracle-Powered Approach
- • Predict resistance 6 months early
- • Preemptive combination therapy
- • 12-month extended response duration
- • Multi-modal therapeutic arsenal
Personalized Cancer Immunotherapy
Immunotherapy Transformation Impact
Honest Framing: What We Can and Cannot Do
Transparent about what's validated and what's not. We focus on mechanism alignment, not outcome prediction.
Validated Capabilities
- Resistance prediction: 2x risk (validated on 469 patients)
- VUS resolution: 73% (validated)
Not Validated
- Outcome prediction: NOT VALIDATED (r=0.037 with PFS)
- Response rate prediction: Mechanism alignment ≠ clinical response
Mechanism Alignment Assessment, Not Outcome Prediction
Our scores reflect how well each drug targets the disrupted pathways in this tumor. They do NOT predict response rates or survival outcomes. We provide biological plausibility, not clinical guarantees.
Get Started with CrisPRO
See how CrisPRO helps resolve VUS uncertainty and improve patient outcomes
Explore CrisPRO Products for Healthcare
Discover how CrisPRO products power transformation across industries